US FDA Suspends All Domestic GMP Surveillance Inspections

Agency responds to COVID-19 pandemic's US arrival by suspending domestic surveillance inspections and non-critical for-cause and preapproval inspections.

FDA entrance sign 2016
FDA Announces Temporary Suspension of Domestic GMP Inspections • Source: Shutterstock

The US Food and Drug Administration announced a suspension of all domestic good manufacturing practice surveillance and non-critical for-cause and preapproval inspections for the duration of the COVID-19 public health crisis as part of decision to require all eligible employees to telework. The aim is to wind down all inspections by 3 April.

Exceptions will be made for inspections of facilities manufacturing medically necessary products, such as products to treat and prevent COVID-19...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance